Home LiteratureArticle Details
PMID: 1084890 Published · ppublish English Comparative Study Journal Article Research Support, U.S. Gov't, P.H.S.

Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

The Journal of clinical investigation ·Vol. 57 ·No. 4 ·1976-04-00 ·Pages 925-37

Switzer ME, McKee PA

Abstract

When purified antihemophilic factor (Factor VIII) was rechromatographed on 4% agarose in 0.15 M NaCl or 1.0 M NaCl, a single protein peak, containing both procoagulant activity and von Willebrand factor activity, as defined by ristocetin-induced platelet aggregation, was eluted in the void volume. Purified Factor VIII immediately lost about 30% of its procoagulant activity when dissolved in 0.25 M CaCl2, and when rechromatographed on 4% agarose in 0.25 M CaCl2, the protein peak and von Willebrand factor activity remained coincident in the void volume; however, most of the remaining procoagulant activity was eluted after the void volume. The elution position of Factor VIII procoagulant activity from 4% agarose in 0.25 M CaCl2, and hence its apparent molecular weight, varied with the protein concentration applied to the column; at low protein concentrations it was eluted close to the inner volume. Yet on Sephadex G-200 in 0.25 M CaCl2, the protein and procoagulant activity were eluted together in the void volume. These observations suggested that the Factor VIII procoagulant activity was not eluting according to size or shape, but was adsorbing to some extent to the agarose. Isolated activity peak material from the 0.25 M CaCl2 columns contained protein and had a typical ultraviolet spectrum. Even at high concentrations, the protein contained no thrombin, Factors IX, X, or Xa activity, or detectable phospholipid. In addition to Factor VIII procoagulant activity, which could be inactivated by a human antibody to Factor VIII, the activity peak protein also contained von Willebrand factor activity. Like native Factor VIII and the void volume protein, the activity peak contained protein that did not enter a sodium dodecyl sulfate 5% polyacrylamide gel in the absence of reducing reagent. After reduction of disulfide bonds, several subunits ranging from 195,000 to 30,000 daltons were observed. These results indicate that the protein in the shifted Factor VIII procoagulant activity peak is large and that its anomalous elution pattern from 4% agarose in 0.25 M CaCl2 results from interaction with the agarose. The Factor VIII-like properties of the activity peak protein and its electrophoretic pattern on sodium dodecyl sulfate gels suggest that it is a species of Factor VIII modified by proteolytic cleavage. These results allow an interpretation that is different from the recently proposed "carrier protein-small active subunit" hypotheses for the structure-function relationships of the Factor VIII molecule.

MeSH Terms
Blood Coagulation/drug effects Blood Proteins/metabolism Calcium Chloride/pharmacology Chemical Phenomena Chemistry Chromatography Chromatography, Agarose Chromatography, Gel Electrophoresis, Polyacrylamide Gel Factor VIII/metabolism,pharmacology Humans Phospholipids/metabolism Polyethylene Glycols/metabolism Sodium Chloride von Willebrand Factor
Chemicals
Blood Proteins Phospholipids von Willebrand Factor Polyethylene Glycols Sodium Chloride Factor VIII Calcium Chloride
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Switzer M E
McKee P A
References (25)
25 references, click to expand
  1. The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid.
    J Biol Chem. 1960 Mar;235:769-75 PMID: 13793161
  2. Protein measurement with the Folin phenol reagent.
    J Biol Chem. 1951 Nov;193(1):265-75 PMID: 14907713
  3. Letter: Experimental model for von Willebrand's disease.
    Nature. 1973 Jun 1;243(5405):293-4 PMID: 4542702
  4. Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity.
    Science. 1973 Dec 14;182(4117):1149-51 PMID: 4127287
  5. The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.
    J Clin Invest. 1974 Nov;54(5):1093-9 PMID: 4213756
  6. The subunit structure of normal and hemophilic factor VIII.
    J Clin Invest. 1973 Sep;52(9):2198-210 PMID: 4199414
  7. Studies on the nature of antihemophilic factor (factor VIII). Further evidence relating the AHF-like antigens in normal and hemophilic plasmas.
    J Clin Invest. 1973 Sep;52(9):2191-7 PMID: 4199413
  8. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    J Clin Invest. 1973 Nov;52(11):2708-16 PMID: 4542944
  9. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    J Clin Invest. 1973 Nov;52(11):2697-707 PMID: 4201262
  10. Nature of von Willebrand factor: a new assay and a specific inhibitor.
    Proc Natl Acad Sci U S A. 1974 Aug;71(8):2937-41 PMID: 4547258
  11. Plasma aggregating factor (bovine) for human platelets: a marker for study of antihemophilic and von Willebrand Factors.
    Proc Natl Acad Sci U S A. 1973 Oct;70(10):2814-8 PMID: 4542779
  12. Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease.
    Nat New Biol. 1972 Mar 29;236(65):104-6 PMID: 4112547
  13. Isolation and characterization of human Factor VIII (antihemophilic factor).
    J Biol Chem. 1973 Jun 10;248(11):3946-55 PMID: 4708094
  14. Studies on the purification of antihemophilic factor (factor VIII). II. Separation of partially purified antihemophilic factor by gel filtration of plasma.
    J Clin Invest. 1969 May;48(5):957-62 PMID: 5780204
  15. Molecular structural studies of human factor VIII.
    Ann N Y Acad Sci. 1975 Jan 20;240:8-33 PMID: 122889
  16. Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide.
    J Biol Chem. 1974 Feb 25;249(4):1173-81 PMID: 4273519
  17. Immunologic studies of antihemophilic factor (AHF, factor VIII). V. Immunologic properties of AHF subunits produced by salt dissociation.
    Blood. 1973 Nov;42(5):737-47 PMID: 4200955
  18. Studies on the purification and characterization of human factor 8.
    J Clin Invest. 1972 Aug;51(8):2151-61 PMID: 4626584
  19. Factor VIII recombination after dissociation by CaCl12.
    Proc Natl Acad Sci U S A. 1973 Aug;70(8):2326-9 PMID: 4525167
  20. Activation of low molecular weight fragment of antihaemophilic factor (factor VIII) by thrombin.
    Nature. 1974 Nov 29;252(5482):404-5 PMID: 4431463
  21. Antihemophilic factor: separation of an active fragment following dissociation by salts or detergents.
    Thromb Diath Haemorrh. 1972 Jul 31;27(3):502-15 PMID: 4662613
  22. Separation of sub-units of antihemophilic factor (AHF) by agarose gel chromatography.
    Thromb Diath Haemorrh. 1972 Apr 30;27(2):212-9 PMID: 5049611
  23. Isolation and some chemical properties of human factor VIII (antihemophilic factor).
    J Lab Clin Med. 1971 Feb;77(2):185-205 PMID: 4993260
  24. Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates.
    Br J Haematol. 1971 Jul;21(1):1-20 PMID: 5559480
  25. Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A.
    J Clin Invest. 1969 Feb;48(2):351-8 PMID: 5812636
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1976-04-00
Pages
925-37
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC436736
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]